Having identified a mechanism facilitating ERK signaling in vivo, we tested the possibility that a selective enhancement of nuclear ERK activity could be neuroprotective in experimental models of neurodegenerative diseases. This evidence concerns the gene MAPK1 and neurodegenerative disease.